Preliminary evidence for curative effect of BCG on chemically induced carcinoma of mammary gland of female albino rat

Pakistan Journal of Zoology

Volumn 44, Issue 2, 2012, Pages 409-414

  Abidi, Taquayya Sultana ^a   Tahir, Mohammad ^a  

^a UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

Author keywords

Carcinogens; Mammary gland carcinoma; Prevention; Rat

Indexed keywords

CANCER; CARCINOGEN; DISEASE CONTROL; EXPERIMENTAL STUDY; FEMALE; HISTOLOGY; RODENT;

ANIMALIA; MYCOBACTERIUM BOVIS BCG; RATTUS; TETRA;

EID: 84859062622     PISSN: 00309923     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. ATHAR, M., AGARWAL, R., WANG, Z. Y., JENEFER, R., LIOYD, J. R., DAVID, R. B. AND MUKHTAR, M., 1991. All trans' retinoic acid protects against conversion of chemically induced and ultraviolet B-radiation induced skin papillomas to carcinomas. Carcinogenesis, 12:2325-2329.
2. ATSDR, September, 1995. Agency for toxic substances and disease registry.
3. CATALONA, W. J., HUDSON, M. A., LISSA, A., GILLEN, D. P., ANDRIOLE, G. L. AND RATLIFF, T. L., 1987. Risks and benefits of repeated course of intravesicle Bacillus Calmette Guerin therapy for superficial bladder cancer. J. Urol., 137:220-224. (Pubitemid 17016634)
4. CEGLOWSKI, W. S. AND FRIEDMAN, H., 1969. Murine virus leukaemogenesis relationship between susceptibility and immunodepression. Nature, 224:1318-1319.
5. CHUNG, M. A., LUO, Y. O., DONNELL, M., RODRIGUEZ, C., HEBER, W., SHARMA, S. AND CHANG, H. R., 2003. Development and pre clinical evaluation of a Bacillus Calmette Guerin Muci based noval breast cancer vaccine. Cancer Res., 63:1280-1287. (Pubitemid 36348706)
6. D'ANCONA, C. A., NETTO, N. R., CLARO, J. A. AND IKARI, O., 1991. Oral or intravesicle Bacillus Calmette Guerin immunophylaxis in bladder carcinoma. J. Urol., 145:498-501.
7. DEMOLS, A., AND VAN LAETHEM, J. L., 2002. Adjuvant chemotherapy for colorectal cancer. Curr, Gastroenterol. Rep., 4:420-426.
8. GIJARE, P. S., RAO, K. V. AND IBHIDE, S. V., 1990. Modulatory effects of snuff, retrinoic acid and Bcarotene on DMBA induced hamster cheek pouch carcinogenesis in relation to keratin expression, Nutr. Cancer, 4:253-259
9. GUADE, G., 2007. National Cancer In time June.
10. HERR, H. W. AND MORALE, A., 2008. History of Bacillus Calmette Guerin and bladder cancer; and immunotherapy success story. J. Urol., 179:53-56. (Pubitemid 350216725)
11. HUPPMANN, M., BAUMGARTEN, A., ZIEGLER, A. G. AND BONIFACIO, E., 2005. Neonatal Bacillus calmette Guerin vaccination and type I diabetes. Diabetes Care, 28:1204-1206. (Pubitemid 40616636)
12. KIMURA, M., 2006. Effect of per orally administered BCG on recurrent breast cancer. J. Surg. Oncol., 20:65-69.
13. KLEIN, G., 1966. Tumour antigens. Ann. Rev. Microbiol., 20:223-252.
14. LAMM, D. L., 2000. Efficacy and safety of Bacillus Calmette Guerin Immunotherapy in superficial, bladder cancer, Clin. Infect. Dis., 31:886-890.
15. LAMM, D. L., BLUMENSTEIN, B., SAROSDY, M. AND GROSSMAN, B., 1997. Significant long-term patient benefit with BCG maintenance therapy. J. Urol., 157:213-225.
16. MARTINEZ-PINEIRO, J. A. AND MUNTANOLA, P., 1977. Non-specific immunotherapy with BCG vaccine in bladder tumors: a preliminary report. Eur. Urol., 3:11-22. (Pubitemid 8048159)
17. MORALES, A. AND NICKEL, J. C., 1986. Immunotherapy of superficial bladder cancer with BCG. World J. Urol., 3:209-214. (Pubitemid 16092090)
18. MOSOLITS, S., NILSSON, B. AND MELLSTEDT, H., 2005. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev. Vaccines, 4:329-350. (Pubitemid 40978696)
19. NOVELLINO, L., CASTELLI, C. AND PARMIANI, G. A., 2005. Listing of human tumour antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother., 54:187-207. (Pubitemid 40174238)
20. PAGANO, F., BASSI, P., PIAZZA, N., ABATANGELO, G., DRAGO FERRANTF, G. L. AND MILANI C., 1995. Improving the efficacy of BCG immunotherapy by dose reduction. Eur. Urol., 27:19-22.
21. PREHN, R. T., 1963. Function of depressed immunologic reactivity during carcinogenesis. J. Natl. Cancer Inst., 31:791-805.
22. REHM, S., 1990. Chemically induced mammary adenomyoepithelioma and myoepithelial tumours. Am. J. Pathol., 136:575-584.
23. SETIA, M. S., STEINMANUS, C. S. AND RUTAERFORD, G. W., 2006. The role of BCG in prevention of leprosy-a matanalysis. Lancet Infect. Dis., 6:162-170. (Pubitemid 43273299)
24. SMITH, R. T., 1968. Tumor-specific immune mechanisms. New Engl. J. Med., 278:1268-1275.
25. SWINSCOW, T. D. N. (ED.), 1983. Statistics at Square One. 8th ed, London; British Medical Association, pp. 54-57.
26. TANGHE, A., CONTENT, J., VANVOOREN, J. P., PORTAELS, F. AND HUYGEN, K., 2001. Protective efficacy of a DNA vaccine encoding antigen 85A from Myocobacterium bovis BCG against buruli ulcer. Infect. Immunol., 69:5403-5411. (Pubitemid 32786472)
27. U. S. E. P. A, 2003. Toxicological review of acetone in support of summary information on integrated risk information system (IRIS), National Center for Environmental Assessment, Washington D. C. EPA/635/R-03/004.